About Poseida Therapeutics
Poseida Therapeutics is a company based in San Diego (United States) founded in 2015 was acquired by Roche in November 2024. Poseida Therapeutics has raised $323.78 million across 6 funding rounds from investors including Fidelity Investments, Roche and Novartis. The company has 259 employees as of December 31, 2022. Poseida Therapeutics offers products and services including piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, and CAR-T Therapy Pipeline. Poseida Therapeutics operates in a competitive market with competitors including Celgene, Denali Therapeutics, MiRagen, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter San Diego, United States
- Employees 259 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Poseida Therapeutics, Inc.
-
Annual Revenue
$64.7 M (USD)-50as on Dec 31, 2023
-
Net Profit
-$123.43 M (USD)-93as on Dec 31, 2023
-
EBITDA
-$129.5 M (USD)-116as on Dec 31, 2023
-
Total Equity Funding
$323.78 M (USD)
in 6 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Aug 07, 2023
-
Investors
Fidelity Investments
& 14 more
-
Employee Count
259
as on Dec 31, 2022
-
Acquired by
Roche
(Nov 26, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Poseida Therapeutics
Poseida Therapeutics offers a comprehensive portfolio of products and services, including piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, and CAR-T Therapy Pipeline.
Inserts large genetic payloads into genomes for therapy development.
Enables accurate edits in cell types for cancer and disease treatments.
Develops allogeneic therapies for relapsed multiple myeloma and cancers.
People of Poseida Therapeutics
Unlock access to complete
Funding Insights of Poseida Therapeutics
Poseida Therapeutics has successfully raised a total of $323.78M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Poseida Therapeutics
Poseida Therapeutics has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Roche and Novartis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Rapha Capital Management is engaged in identifying and investing in biopharmaceutical companies.
|
Locked | Locked | Locked | |
|
Web application services requiring JavaScript, along with potential agricultural-related offerings.
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked |
Investor details for Poseida Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Poseida Therapeutics
Investment portfolio details for Poseida Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Poseida Therapeutics
Detailed financials for Poseida Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Poseida Therapeutics Comparisons
Peer comparison for Poseida Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Poseida Therapeutics
Poseida Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celgene, Denali Therapeutics, MiRagen, Juno Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for cancer and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
Detailed competitors of Poseida Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Poseida Therapeutics
Complete news archive for Poseida Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Poseida Therapeutics
Poseida Therapeutics was founded in 2015.
Poseida Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Poseida Therapeutics is a funded company, having raised a total of $323.78M across 6 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Poseida Therapeutics is 259.
Annual revenue of Poseida Therapeutics is $64.7M as on Dec 31, 2023.
Poseida Therapeutics was founded in 2015 and is based in San Diego, United States. Operations focus on the biotechnology sector, where CAR-T and gene therapy products are developed for cancer and orphan liver diseases. Genome engineering is applied to silence target genes or insert therapeutic ones. Proprietary tools such as the piggyBac DNA Modification System, CRISPR, TALEN, and Footprint-Free Gene Editing System are utilized for precise, synthetic, and virus-free modifications.
Poseida Therapeutics's top competitors include Juno Therapeutics, Senti Biosciences and Denali Therapeutics.
Poseida Therapeutics offers piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, and CAR-T Therapy Pipeline.
Poseida Therapeutics has 15 investors. Key investors include Fidelity Investments, Roche, Novartis, Astellas Pharma, and Perceptive Advisors.